Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]

• Main Authors: Restelli U (Author), Fabbiani M (Author), Di Giambenedetto S (Author), Nappi C (Author), Croce D (Author)
• Format: Book
• Published: Dove Medical Press, 2017-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D. Clinicoecon Outcomes Res. 2017;9:173–179.  On page 174, Methods section, 1st paragraph, the last sentence reads “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived f...